Kaneka Corporation has announced that it has begun sales of its i-ED brain aneurysm embolisation coil in Europe, as of October 2025.
The product obtained CE certification under EU Medical Device Regulation (MDR) in July and will be distributed primarily in Europe through Kaneka Medical Europe.
As detailed in a recent press release from the company, the i-ED coil provides “world-class” flexibility, owing to its specialised wire thickness and structural features, enabling coils to be packed more densely within aneurysms as compared to conventional products, as well as accommodating the treatment of irregularly shaped aneurysms.
Its role in reducing the risk of aneurysm rupture is highly regarded by physicians and, since the device’s launch on the Japanese market in 2019, sales have continued to grow steadily, Kaneka also claims.
The company says it is expanding its business across a wide range of fields, including via devices for the treatment of cardiac, peripheral vascular and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases—with a key goal being for its Health Care Solution Unit to achieve ¥300 billion in sales by 2030.
